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Abstract 
Dent disease (DD) is a rare X-linked recessive renal tubulopathy characterised by low-molecular-weight proteinuria 
(LMWP), hypercalciuria, nephrocalcinosis and/or nephrolithiasis. DD is caused by mutations in both the CLCN5 and 
OCRL genes. CLCN5 encodes the electrogenic chloride/proton exchanger ClC-5 which is involved in the tubular reab-
sorption of albumin and LMW proteins, OCRL encodes the inositol polyphosphate 5-phosphatase, and was initially 
associated with Lowe syndrome. In approximately 25 % of patients, no CLCN5 and OCRL mutations were detected. 
The aim of our study was to evaluate whether calcium phosphate metabolism disorders and their clinical complica-
tions are differently distributed among DD patients with and without CLCN5 mutations. Sixty-four male subjects were 
studied and classified into three groups: Group I (with CLCN5 mutations), Group II (without CLCN5 mutations) and 
Group III (family members with the same CLCN5 mutation). LMWP, hypercalciuria and phosphaturic tubulopathy and 
the consequent clinical complications nephrocalcinosis, nephrolithiasis, bone disorders, and chronic kidney disease 
(CKD) were considered present or absent in each patient. We found that the distribution of nephrolithiasis, bone dis-
orders and CKD differs among patients with and without CLCN5 mutations. Only in patients harbouring CLCN5 muta-
tions was age-independent nephrolithiasis associated with hypercalciuria, suggesting that nephrolithiasis is linked 
to altered proximal tubular function caused by a loss of ClC-5 function, in agreement with ClC-5 KO animal models. 
Similarly, only in patients harbouring CLCN5 mutations was age-independent kidney failure associated with nephro-
calcinosis, suggesting that kidney failure is the consequence of a ClC-5 dysfunction, as in ClC-5 KO animal models. 
Bone disorders are a relevant feature of DD phenotype, as patients were mainly young males and this complication 
occurred independently of age. The triad of symptoms, LMWP, hypercalciuria, and nephrocalcinosis, was present in 
almost all patients with CLCN5 mutations but not in those without CLCN5 mutations. This lack of homogeneity of 
clinical manifestations suggests that the difference in phenotypes between the two groups might reflect different 
pathophysiological mechanisms, probably depending on the diverse genes involved. Overall, our results might sug-
gest that in patients without CLCN5 mutations several genes instead of the prospected third DD underpin patients’ 
phenotypes.
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Background
Dent disease (DD) is a rare X-linked recessive renal 
tubulopathy characterised by low-molecular-weight 
proteinuria (LMWP) and is often associated with hyper-
calciuria, nephrocalcinosis and/or nephrolithiasis. 
Additional tubular defects, such as hyperphosphaturia, 
glycosuria and aminoaciduria, may also be observed 
(Devuyst and Thakker 2010). Progression to chronic kid-
ney disease (CKD) and renal failure occurs between the 
3rd and 5th decades of life in 30–80 % of male patients 
(Wrong et al. 1994; Lloyd et al. 1997; Thakker 2000). Signs 
generally manifest in childhood or in early adult life. The 
presentation of DD appears variable: a universal feature is 
proteinuria, but other presenting features in children and 
adolescents include nephrocalcinosis and hypercalciuria, 
with or without nephrolithiasis, although the relationship 
between nephrocalcinosis and stone formation remains 
unclear. Hypophosphataemia and bone disorders (BDs) 
have also been observed but appear to be a less promi-
nent feature of the phenotype than originally thought. 
In adulthood, the disease is suspected in most cases due 
to the presence of nephrocalcinosis/nephrolithiasis or 
unexplained CKD in subjects with hypercalciuria or in 
the context of familial cases of CKD and/or nephrolithi-
asis (Edvardsson et al. 2013; Ferraro et al. 2013).
DD is caused by mutations in the CLCN5 gene, which 
encodes the electrogenic chloride/proton exchanger 
ClC-5 (this condition is now called Dent disease 1, 
OMIM 300009) (DD1). In the human kidney, ClC-5 is 
primarily expressed in proximal tubular cells (PTCs), pre-
dominantly located in the subapical endosomes, which 
are involved in the endocytic reabsorption of albumin 
and LMW proteins (Jouret et al. 2004; Picollo and Pusch 
2005). To date, more than 200 different mutations have 
been reported in the CLCN5 gene (Mansour-Hendili 
et al. 2015). However, in approximately 40 % of patients 
with the classic DD phenotype, no CLCN5 gene muta-
tions have been detected. Mutations in the OCRL gene, 
encoding the inositol polyphosphate 5-phosphatase, ini-
tially associated with Lowe syndrome, account for 15  % 
of the patients now classified as having Dent disease 2 
(DD2) (OMIM 300555) (Hoopes et  al. 2004, 2005). The 
spectrum of symptoms in DD2 can range from appar-
ent exclusive kidney manifestations to the involvement 
of other tissues, notably brain and muscle, as in Lowe 
syndrome (Hichri et  al. 2011). Approximately 25  % of 
patients, however, do not harbour mutations in CLCN5 
or OCRL (Hoopes et al. 2004, 2005; Tosetto et al. 2009a, 
b). Genotype–phenotype correlations have yet to be 
established. Whereas ClC-5 knock-out (KO) models 
recapitulated the major features of DD (Silva et al. 2003; 
Sayer et  al. 2004), the OCRL1 KO mice did not (Jänne 
et al. 1998). For this reason, the pathogenic mechanisms 
through which the loss of OCRL1 function leads to DD 
are not yet deeply understood (Mehta et al. 2014).
The aim of our study was to evaluate whether calcium 
phosphate metabolism disorders and their clinical com-
plications are differently distributed among DD patients 
with and without CLCN5 mutations.
Results
On the basis of the genetic analysis and recruitment cri-
teria (unrelated or familial case), the patients were classi-
fied into three groups: Group I, 41 patients (20 adults and 
21 children) with CLCN5 mutations (CLCN5+); Group 
II, 17 patients (8 adults and 9 children) without CLCN5 
mutations (CLCN5−); Group III, the 6 family members 
(4 adults and 2 children) who carried the same CLCN5 
mutation (CLCN5+ family).
The frequencies of the seven clinical signs consid-
ered were calculated, and their absolute and percent-
age values in the three groups are shown in Table  1. In 
descending order of frequency, these signs were LMWP 
98.4  %, hypercalciuria 85.9  %, nephrocalcinosis 71.9  %, 
phosphaturic tubulopathy 40.6 %, bone disorders 34.4 %, 
nephrolithiasis 29.7  %, and CKD 14.1  %. However, the 
frequencies were differed somewhat among the three 
groups, except for LMWP, which was present in 100 % of 
the cases in Groups I and II, given that it was required 
for recruitment, and in 83.3 % of the subjects in Group 
III (5/6), who were recruited because of family history 
and genetic positivity. Nephrolithiasis was quite rare in 
our patients, being detected in only 26.8 % of the patients 
in Group I and in 29.4 % of Group II. BDs were found in 
41.5 % of the patients in Group I, in 29.4 % in Group II, 
and in none of the patients in Group III. Only 2 out of 
17 patients presenting with BDs of Group I had a T-score 
<−2.5. CKD was observed in 12.2  % of the Group I 
patients, in 23.5 % of Group II, and in none of the Group 
III patients. Positive family history of nephropathy was 
equally distributed in the first two groups and specifically 
in 48.3  % of the 58 patients belonging to the combined 
groups.
To evaluate the transversal distribution of calcium 
phosphate metabolism disorders and their complications, 
we compared the frequencies of each clinical sign in the 
three groups. A comparison among groups revealed that 
nephrocalcinosis (p < 0.001) and hypercalciuria (p < 0.01) 
were more frequent in Group I than in Group II and 
more frequent in Group I than III (p = 0.05 and p < 0.01, 
respectively).
No association was found between age and the pres-
ence of the various signs considered in either the 
CLCN5+ or CLCN5− group. Nephrolithiasis, however, 
was significantly (p  =  0.011) more frequent in adults 
(12/28) than in children (3/30), but the median age of 
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adult patients with nephrolithiasis was significantly lower 
in CLCN5+ than in CLCN5− group (23 vs. 42 p = 0.012). 
In contrast, in the CLCN5+ family, nephrolithiasis was 
present only in the three adults aged 38–46 years.
Associations between two clinical signs within a sin-
gle group were found between nephrocalcinosis and 
nephrolithiasis (p  <  0.0001) and between hypercalciuria 
and nephrolithiasis (p  <  0.0001) in Group I. Whereas 
the association between nephrocalcinosis and CKD was 
significant in Group I (p < 0.0001), it was not in Group 
II, whose patients presented with CKD more frequently 
(23.5 vs. 12.2 %). BDs were not associated with any of the 
other parameters studied in Groups I and II, and they 
were not present in any of the patients in Group III.
Discussion
Although we found a low number of significant differ-
ences, the distribution of the clinical signs among the 
three groups of patients seems to reveal different renal 
phenotypes. Whereas in Group I the predominant phe-
notype was characterised by hypercalciuria and nephroc-
alcinosis, in Group II and III, it was better represented by 
a phosphaturic tubulopathy.
Hypercalciuria and nephrocalcinosis, which together 
with LMWP represent the main clinical manifestations 
in our DD1 patients and patients in the literature, were 
not frequent in CLCN5− patients. Particularly, nephro-
calcinosis had a low frequency that was similar to that 
observed by Bokenkamp et al. (2009) in DD patients har-
bouring OCRL mutations. Claverie-Martín et  al. (2011) 
reported a frequency of rickets and osteomalacia in DD1 
patients similar to ours. CKD is reported to occur in more 
than two-thirds of DD1-affected males, a frequency much 
higher than ours, but we classified our patients as hav-
ing CKD only when CKD was clearly evident and stable 
(CKD stage 3). In our DD1 patients, nephrolithiasis was 
not as frequent as nephrocalcinosis (26.8 vs. 87.8  %, 
respectively). Also the meta-analysis of Claverie-Martín 
et al. (2011) reported that nephrolithiasis occurs in DD1 
patients less frequent than nephrocalcinosis (41 vs. 76 %).
Although the absence of metabolic abnormalities 
linked to calcium phosphate metabolism in patients with 
relapsing or recurring episodes of idiopathic calcium 
nephrolithiasis is rather frequent—higher than 40 % (per-
sonal unpublished data)—nephrolithiasis in DD patients 
should, by definition, always be secondary to tubulopa-
thy. In fact, kidney stones without metabolic abnor-
malities were identified sporadically in all three groups. 
However, hypercalciuria, the most important metabolic 
abnormality associated with Dent disease (Devuyst and 
Thakker 2010), was associated with concomitant nephro-
lithiasis only in CLCN5+ patients.
A family history of nephropathy was present in approx-
imately half of our patients, and it was equally frequent 
in Groups I and II, further confirming the importance 
of genetic background in Group II. A family history of 
nephrolithiasis is highly variable in stone formers (Gam-
baro et  al. 2004). Kidney stones are a heterogeneous 
disease, but our patients were selected based on having 
a genetic disease, and this is why positive family history 
was so frequent.
Subdividing patients into CLCN5-positive and -nega-
tive groups allowed us to evaluate whether different 
genetic backgrounds were linked to different clinical 
and metabolic profiles. In fact, whereas in patients with 
CLCN5 mutations the pathogenesis of DD was linked 
to modifications in the chloride/proton exchanger ClC-
5, with consequent alterations in the PTC endocytic 
processes, in CLCN5 and OCRL-negative patients, the 
pathogenesis of the disease remained unclear.
Table 1 Absolute and percentage values of the seven clinical signs considered
Group I versus Group II: * p < 0.001, ** p < 0.01. Group I versus Group III: §  p = 0.05, §§ p < 0.01
Total patients Group I Group II Group III
Number % Number % Number % Number %
Males 64 41 17 6
Median age 16 ± 12 14 ± 9 18 ± 16 27 ± 16
Range 1–58 years 1–43 years 2–58 years 2–46 years
LMWP 63 98.4 41 100 17 100 5 83.3
Nephrocalcinosis 46 71.9 36 87.8*§ 7 41.2 3 50
Nepholithiasis 19 29.7 11 26.8 5 29.4 3 50
Hypercalciuria 55 85.9 40 97.6**§§ 12 70.6 3 50
Phosphaturic tubulopathy 26 40.6 13 31.7 9 52.9 4 66.7
Bone disorders 22 34.4 17 41.5 5 29.4 0 0
Kidney failure 9 14.1 5 12.2 4 23.5 0 0
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The family group was separated from the patients in 
Group I to verify whether the disease’s clinical aspects in 
the family with the same CLCN5 mutation overlapped 
with those found in the forty-one unrelated patients with 
different CLCN5 mutations and, if the phenotype expres-
sion was different, to specify how. In fact, only one of 
the family members presented with manifest signs of the 
disease, whereas none of the other six were suspected of 
having DD despite their ages and did not exhibit clinical 
signs that were consistent with the DD phenotype.
The defining characteristic of DD is the presence of 
LMWP. In our patients, only one out of 64 did not present 
with LMWP. This patient was a 12-year-old male, belong-
ing to the family group, who at the time of recruitment did 
not show any of the clinical signs considered. To our knowl-
edge, this is the second case reported of a DD patient not 
presenting with LMWP (Scheinman et al. 2000). Of note, 
this subject subsequently and gradually manifested higher 
LMWP, which even exceeded 5 times the initial value that 
we measured. His delayed manifestation of LMWP and of 
other disease symptoms strongly supports the presence of 
modifier genes modulating disease expression. In line with 
this hypothesis is the fact that in this family none of the het-
erozygous females presented with LMWP.
Nephrocalcinosis, present at an elevated frequency 
in our population and significantly higher in CLCN5+ 
patients with respect to the CLCN5− subjects, was absent 
in only four of the CLCN5+ patients, three of whom 
were of preschool or school age and might presumably 
develop this clinical sign at a later date. Nephrocalcinosis 
was associated with hypercalciuria in Group I, and both 
were significantly more frequent than in Group II. These 
data suggest that the different genotypes—mutations of 
CLCN5 in Group I and of other genes (different from 
CLCN5 and OCRL genes) in Group II—may be respon-
sible for the different frequencies of intraparenchymal 
calcium deposition. Within the family group, however, 
the presence of nephrocalcinosis was significantly lower 
compared to Group I, although the underlying patho-
genic mechanisms should be the same. Again, it could be 
rationally hypothesised that modifying genes contributed 
to this lighter phenotypic expression.
Unlike the relatively low but numerically similar fre-
quency of nephrolithiasis and nephrocalcinosis in 
Groups II and III, in Group I, the presence of nephro-
lithiasis was much lower than that of nephrocalcinosis, 
although in this group, nephrolithiasis, when present, 
was practically always associated with nephrocalcinosis. 
Thus, nephrolithiasis appears to be a direct consequence 
of nephrocalcinosis and is also accompanied by hyper-
calciuria. Therefore, nephrolithiasis was linked to hyper-
calciuria in Group I as an expression of the PTC damage 
and a consequence of the dysfunction of the chloride/
proton exchanger CIC-5. Our results, then, may confirm 
in humans what has been shown in different ClC-5 KO 
animal models and in  vitro studies (Wang et  al. 2000; 
Silva et al. 2003; Sayer et al. 2004).
In contrast to Group I, in Groups II and III, nephro-
lithiasis seemed to be an independent manifestation of 
nephrocalcinosis, mostly being present in adults. Thus, 
in the majority of CLCN5− patients and in the CLCN5+ 
family, nephrolithiasis was associated neither with 
nephrocalcinosis nor with hypercalciuria. According to 
our data, in these patients, nephrolithiasis appeared to 
follow a different pathogenic pathway with respect to the 
patients of Group I.
Hypercalciuria is frequent in patients affected by DD1 
and is an important diagnostic parameter. This relation 
suggests a substantially proximal tubular dysfunction, 
either through an indirect mechanism mediated by vita-
min D (Silva et al. 2003) or through the derangement of 
calcium reabsorption in the PTCs by endocytosis (Fried-
man 1999; Devuyst et al. 1999) both being due to the loss 
of CIC-5 function. The mechanism by which hypercalci-
uria arises in CLCN5− patients is unknown, but the sig-
nificantly lower frequency with which it was found in our 
CLCN5− patients with respect to the CLCN5+ patients 
suggests that the endocytosis-mediated proximal calcium 
reabsorption is intact.
In the entire sample of DD patients, BDs were not asso-
ciated with any of the parameters considered, but they 
were nevertheless observed in more than 30  % of our 
patients. This is undoubtedly a relevant finding consid-
ering that all patients were males with a median age of 
16 and that this complication occurred independently of 
age. Furthermore, BDs were neither significantly differ-
ent between the CLCN5+ and CLCN5− patients nor sig-
nificantly associated with the presence of hypercalciuria. 
It is noteworthy, however, that in children with CLCN5 
mutations the clinical finding of rickets were present in 
9 out of 21, almost two time more frequent than in chil-
dren without CLCN5 mutations where only 2 out of 9 
presented with rickets. In the family, the total absence 
of BDs suggests a shared genetic background protecting 
against bone demineralisation. The fact that the hete-
rozygous females of the family had even higher bone den-
sity than normal reference parameters may support this 
hypothesis (data not shown).
Similarly, CKD was absent in all 6 members of the fam-
ily, even in those with nephrocalcinosis and/or nephro-
lithiasis who were old enough that the renal dysfunction 
could have already evolved into CKD. This observation is 
notable in consideration of the existence of a one-year-
old infant with CKD in Group I. Once again, important 
modifier genes may have influenced disease expression in 
the CLCN5+ family.
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That DD is a hereditary form of nephrolithiasis associ-
ated with CKD is well known (Edvardsson et  al. 2013). 
Two large families were described in the 1990s by Fry-
moyer et al. (1991) and Wrong et al. (1994). These authors 
found that nephrolithiasis and CKD segregated as an 
X-linked recessive trait. The pathogenic mechanism lead-
ing to CKD in DD patients, however, is not completely 
understood. The most popular hypothesis is that renal 
calcium deposits lead to CKD through a chronic intersti-
tial inflammation developing into fibrosis (Cebotaru et al. 
2005). Our findings confirm this hypothesis only in part. 
Supporting this hypothesis are the data from Group I, in 
which all subjects with CKD had concomitant nephrocal-
cinosis, and the occurrence of CKD was not age-related. 
At odds with the hypothesis is the finding that the major-
ity of patients with CKD belonged to the CLCN5− group, 
in which this complication was not associated with 
nephrocalcinosis.
On the basis of these findings, an alternative hypothesis 
can be advanced: the genes involved in the development 
of the DD phenotype in the CLCN5− patients cause CKD 
through mechanisms other than those in the CLCN5+ 
patients, where the associations between hypercalciu-
ria and nephrocalcinosis and between nephrocalcino-
sis and CKD seem to indicate the direct involvement of 
the ClC-5 alteration in the pathogenesis of nephrocalci-
nosis and subsequent CKD, as shown in animal models 
(Cebotaru et al. 2005).
Conclusions
Our data indicate that the distribution of seven clinical 
signs, particularly of the 4 main complications that typi-
cally characterise DD, is different among the two geno-
typically different groups. This fact might indicate that 
although the clinical manifestations appear rather simi-
lar, the pathogenesis is different, probably depending on 
the diverse genes involved.
In fact, the triad of symptoms, LMWP, hypercalciuria, 
and nephrocalcinosis, was present in almost all patients 
of Group I, indicating that the loss of ClC-5 function 
was the cause of clinical manifestations independently of 
allele heterogeneity, thus mimicking the picture shown in 
the ClC-5 KO mouse models. This situation might not be 
true for patients of Group II, who should harbour muta-
tions in different gene/genes. This lack of homogeneity of 
clinical manifestations might suggest that several genes 
underpin our patients’ phenotypes instead of the pros-
pected third DD gene.
Clinical symptoms in the CLCN5+ family members 
are quite variable and more similar to those of Group 
II, although a common CLCN5 mutation segregates in 
the family’s affected members. To explain this atypical 
picture, the presence of a shared genetic background 
(modifier genes) modifying the DD1 phenotypic manifes-
tations should be strongly suspected.
Patients and methods
Patients
Sixty-four male subjects were evaluated: 58 unrelated 
patients came to our attention because of the suspi-
cion of DD, and 6 were recruited because they were 
relatives of one of these patients and were positive for a 
CLCN5 mutation. The latter six patients did not come 
to our attention because of evident DD symptomatology 
but because they were related to one of the 58 patients 
who was the only one in the family to have shown a DD 
phenotype.
In this study, the DD phenotype was defined as a clini-
cal picture characterised by an association of LMWP 
with hypercalciuria and/or at least one of the following: 
nephrocalcinosis, nephrolithiasis, phosphaturic tubulop-
athy, BDs, CKD as well as family history of nephropathy 
(Tosetto et al. 2006).
The nephrology centres across Italy that followed these 
patients provided us with clinical and laboratory data. 
Based on the analysis of these data, we utilised three 
clinical/metabolic signs (LMWP, hypercalciuria and 
phosphaturic tubulopathy) and four clinical complica-
tions (nephrolithiasis, nephrocalcinosis, BDs, and CKD) 
that, together with family history of nephropathy, were 
recorded as present or absent in each patient. The mean 
age of patients was 16 ±  12  years (1–58  years). Thirty-
two were children, age <14  years. All the 64 patients 
were males, because the disease is known to be transmit-
ted as an X-linked recessive trait. However, in almost all 
patients evidence of an X-linked disease transmission 
was absent. The study was conducted according to the 
principles of the Helsinki Declaration and was approved 
by the local IRB.
Definitions
LMWP was qualitatively evaluated as 24-h urinary 
increased excretion of β2-microglobulin (at least five 
times higher than the normal value of <300  µg/day), 
although in some cases the increase was lower than that 
typical in DD.
Hypercalciuria was defined as fasting and absolute (uri-
nary calcium excretion >300 mg/day in adults or >4 mg 
per kg of bodyweight in children per day). Phosphaturic 
tubulopathy was defined as persistent hypophosphatemia 
in the presence of a decrease tubular reabsorption of 
phosphate (TRP <80  %) and/or reduced renal threshold 
phosphate concentration (TmPO4/GFR).
Nephrolithiasis was attributed if a stone had been 
passed or removed or shown in the urinary tract by X-ray 
or ultrasound imaging. Nephrocalcinosis was defined 
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as diffuse, fine, renal parenchyma calcification on X-ray 
and/or ultrasound examinations.
Bone disorders are defined as the presence of rick-
ets or bone demineralisation. Rickets were evaluated in 
children during the physical and skeletal radiological 
examinations and bone demineralisation in adults by 
measuring bone density of the lumbar spine and femo-
ral neck using dual energy X-ray absorptiometry (DEXA) 
(T-score <−1.5 SD).
CKD in both children and adults was attributed when 
creatinine clearance (CCr) was <60  ml/min/1.73  m2 
(CKD stage 3). In all our patients parathyroid hormone 
(normal range 10–65  ng/l in adults and 10–55  ng/l in 
children) and serum calcium were normal. None of our 
patients had CCr <30 ml/min/1.73 m2.
Family history was considered positive when a 
nephropathy—most frequently nephrolithiasis or CKD—
was present in one or more family members.
Clinical diagnosis of DD was considered “probable” 
when the patient presented with LMWP and hypercal-
ciuria in association with at least one of the other signs 
indicated above and “possible” when the patient pre-
sented with LMWP with at least one of the other signs 
and in the absence of hypercalciuria (Tosetto et al. 2006).
Molecular analysis, based on the assessment of CLCN5 
and OCRL mutations (Tosetto et  al. 2006, 2009a) 
detected 37 different CLCN5 mutations and confirmed a 
DD1 clinical diagnosis in 41 out of the 58 suspected DD 
patients (for molecular genetic details see refs. Tosetto 
et al. 2006, 2009b). Seventeen patients did not carry any 
CLCN5 mutation. Mutational screening of OCRL gene 
did not reveal any mutation. Cascade genetic screen-
ing was conducted in 11 male subjects of the family 
because they were sons of the heterozygous females, and 
6 resulted to carry the same G260V CLCN5 mutation as 
the proband (Anglani et al. 2006).
Statistics
The McNemar test was used to evaluate the significance 
with which two clinical signs in the same group were 
associated. Fisher’s exact test was used for small samples 
not numerically adequate for the χ2 test. The χ2 test was 
used to assess the variation in the frequency of the same 
clinical sign in two different groups to indicate the non-
randomness of the difference and, therefore, the lack of 
homogeneity of the two classes being examined. The χ2 
test was also applied to evaluate the association between 
age and the presence of various clinical signs in each of 
the three groups considered.
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